A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)

In brief

THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).

Key facts

Study ID

NCT03018405

Run by

Celyad Oncology SA

People needed

146

Starts

2016-12-01

Expected to finish

2021-08-01

Last updated by the study team

2019-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Tampa, Florida, United States (enrolling)
• Study site — Buffalo, New York, United States (enrolling)
• Study site — Brussels, Belgium (enrolling)
• Study site — Brussels, Belgium (enrolling)
• Study site — Ghent, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.